162 related articles for article (PubMed ID: 9443625)
1. Population pharmacokinetics of total and unbound etoposide.
Nguyen L; Chatelut E; Chevreau C; Tranchand B; Lochon I; Bachaud JM; Pujol A; Houin G; Bugat R; Canal P
Cancer Chemother Pharmacol; 1998; 41(2):125-32. PubMed ID: 9443625
[TBL] [Abstract][Full Text] [Related]
2. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
4. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
5. Disposition of total and unbound etoposide following high-dose therapy.
Schwinghammer TL; Fleming RA; Rosenfeld CS; Przepiorka D; Shadduck RK; Bloom EJ; Stewart CF
Cancer Chemother Pharmacol; 1993; 32(4):273-8. PubMed ID: 8324869
[TBL] [Abstract][Full Text] [Related]
6. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.
Stewart CF; Arbuck SG; Fleming RA; Evans WE
J Clin Oncol; 1990 Nov; 8(11):1874-9. PubMed ID: 2230875
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability and pharmacokinetic features of etoposide in childhood acute lymphoblastic leukemia patients.
Chen CL; Rawwas J; Sorrell A; Eddy L; Uckun FM
Leuk Lymphoma; 2001 Jul; 42(3):317-27. PubMed ID: 11699396
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics and pharmacodynamics of oral etoposide.
Toffoli G; Corona G; Sorio R; Robieux I; Basso B; Colussi AM; Boiocchi M
Br J Clin Pharmacol; 2001 Nov; 52(5):511-9. PubMed ID: 11736859
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetic approach to compare oral and i.v. administration of etoposide.
Würthwein G; Krümpelmann S; Tillmann B; Real E; Schulze-Westhoff P; Jürgens H; Boos J
Anticancer Drugs; 1999 Oct; 10(9):807-14. PubMed ID: 10587290
[TBL] [Abstract][Full Text] [Related]
11. Effect of grapefruit juice intake on etoposide bioavailability.
Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL
Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073
[TBL] [Abstract][Full Text] [Related]
12. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetic aspects of oral administration of etoposide].
Tillmann B; Krümpelmann S; Würthwein G; Wagner A; Schulze-Westhoff P; Hempel G; Jürgens H; Boos J
Klin Padiatr; 1998; 210(4):159-64. PubMed ID: 9743946
[TBL] [Abstract][Full Text] [Related]
14. Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats.
Li X; Choi JS
Anticancer Res; 2009 Apr; 29(4):1411-5. PubMed ID: 19414395
[TBL] [Abstract][Full Text] [Related]
15. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
Variol P; Nguyen L; Tranchand B; Puozzo C
Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
[TBL] [Abstract][Full Text] [Related]
16. Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children.
Kersting G; Willmann S; Würthwein G; Lippert J; Boos J; Hempel G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):397-405. PubMed ID: 21789689
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of etoposide with intravenous drug administration in children and adolescents.
Kato Y; Nishimura S; Sakura N; Ueda K
Pediatr Int; 2003 Feb; 45(1):74-9. PubMed ID: 12654074
[TBL] [Abstract][Full Text] [Related]
18. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and bioequivalence of etoposide following intravenous administration of etoposide phosphate and etoposide in patients with solid tumors.
Kaul S; Igwemezie LN; Stewart DJ; Fields SZ; Kosty M; Levithan N; Bukowski R; Gandara D; Goss G; O'Dwyer P
J Clin Oncol; 1995 Nov; 13(11):2835-41. PubMed ID: 7595746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]